Eye Melanoma Market Size

Eye Melanoma Market Overview

Eye Melanoma Market Size was valued at USD 5.4 Billion in 2023. The Global Eye Melanoma industry is projected to grow from USD 6.7 Billion in 2024 to USD 10.2 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.87% during the forecast period (2024 - 2032).

Melanoma is the cancer of melanin-producing cells. Eye melanoma or ocular melanoma can develop in the middle of the three layers of the eye, i.e., in between the sclera, retina, and uvea. The diseased layers of the eye cannot be visually examined, making the diagnosis of the disease difficult. The sensation of flashing lights, blurry vision in one eye, and loss of peripheral vision are some of the common symptoms of the eye melanoma. Increasing prevalence of the eye cancer and growing geriatric population are the major drivers of the market growth. According to the Cancer Research U.K, approximately 750 new cases of eye cancer were reported on a yearly basis within the U.K from 2013-2015.

Moreover, it was estimated that from the last decade, the prevalence of eye cancer has increased by 25% in the U.K. Additionally, rising healthcare expenditures and increasing research and development investments by the major players of the market boosts the market growth. However, lack of awareness, high diagnostics, and surgical procedures costs are estimated to restrain the market growth during the forecast period. The cost of the therapeutic procedures like laser iridotomy is estimated to be around USD 1,068 to USD 1,188. This makes such procedures an out of pocket concern for many patients.

In October 2023, iOnctura, a biotech company in the clinical stage, obtained authorization from the US Food and Drug Administration (FDA) to conduct investigations on a medication designed to address uncommon malignancies. The FDA has authorized the Swiss business to conduct clinical trials on Roginolisib (IOA-244) as part of its investigational new drug (IND) application. This application is intended to treat various illnesses, including solid and haematologic malignancies, such as uveal melanoma. Uveal melanoma is an uncommon type of cancer that occurs when cancerous cells develop in the uveal tract of the eye. This condition has a roughly 50% likelihood of spreading to other parts of the body, resulting in a projected survival time of only one year for most patients. iOnctura claims that their medicine is the initial innovative allosteric modulator of PI3Kδ. It possesses a distinctive binding style and strong selectivity for the target molecule, which is expected to enhance safety and tolerability compared to past treatments for the same condition.

Eye Melanoma Market Segmentation

The eye melanoma market is segmented on the basis of the site, diagnosis, treatment, and end user.

Eye Melanoma Site Insights

On the basis of the site, the Eye Melanoma Market is segmented into sclera, retina, uvea, and others.

Eye Melanoma Diagnosis Insights

On the basis of the diagnosis, the market is categorized into eye exam, imaging, biopsy, and others. The eye exam segment is further categorized into ophthalmoscopy, slit-lamp biomicroscopy, and others. The imaging is sub-segmented into ultrasound, fluorescein angiography, fundus autofluorescence, optical coherence tomography, and others. On the basis of the treatment, the market is segmented into radiation therapy, laser treatment, surgery, and others. The radiation therapy segment is sub-segmented into episcleral plaque therapy, external beam radiation therapy, and others. The external beam radiation therapy is further segmented into conformal proton beam radiation therapy, stereotactic radiosurgery, and others. The surgery segment is sub-segmented into iridectomy, choroidectomy, enucleation, and others. On the basis of the end users, the market is segmented into hospitals & clinics, academic institutes, and others.

Eye Melanoma Regional Insights

America dominates the eye melanoma market owing to the presence of a well-developed healthcare sector and huge patient population. Apart from this, increasing number of patients, changing lifestyle, and increasing healthcare expenditure have boosted the growth of the American market. Additionally, the presence of the major market players like the GENERAL ELECTRIC, Analogic Corporation, NOVADAQ Technologies Inc. within the region fuels the market growth.

Europe is the second largest eye melanoma market. Factors such as increasing availability of funds for research, well-developed healthcare sector, huge patient population, and growing geriatric population are estimated to drive the market growth within the region. According to the Office for National Statistics the geriatric population within the U.K is estimated to reach approximately 69.8 billion by 2026 from 65.6 billion in 2016. 

The Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies and rising healthcare expenditure. In countries like India, the presence of huge opportunities along with favorable government policies fuels the market growth.

The Middle East & Africa has the least share in the eye melanoma market due to the presence of poor economies and stringent government policies, especially in the Africa region. The Middle East holds a majority of the market due to a well-developed healthcare sector and huge healthcare expenditure by economies like Dubai, Kuwait, Dubai, and others.

Key Players in the Eye Melanoma Market 

The key players for the eye melanoma market are: 

• Castle Biosciences, Inc. (U.S.)


• GENERAL ELECTRIC (U.S.)


• Koninklijke Philips N.V. (The Netherlands)


• TOSHIBA CORPORATION (Japan)


• Siemens AG (Germany)


• Analogic Corporation (U.S.)


• Optovue Incorporated (U.S.)


• NOVADAQ Technologies Inc. (Canada)


• Agfa-Gevaert Group (Belgium)


• ZEISS (Germany)

Intended Audience

• Pharmaceutical companies


• Biotechnological institutes


• Government and Private Laboratories


• Research and Development (R&D) Companies


• Medical Research Laboratories


• Market Research and Consulting Service Providers